Aciclovir Sandoz, tablets 200 mg 25 pcs

Pharmgroup:

an antiviral agent.

Pharmic action:

The antiviral drug is a synthetic analog of thymidine nucleoside.

In infected cells containing viral thymidine kinase is phosphorylated and converted into acyclovir monophosphate. Under the influence of guanylate cyclase acyclovir monophosphate is converted into diphosphate and under the influence of several cellular enzymes into triphosphate. High selectivity and low toxicity for humans is caused by the absence of necessary enzyme for formation of acyclovir triphosphate in intact cells of macroorganism.

Aciclovir triphosphate, “being built” into the DNA synthesized by the virus, blocks virus multiplication. Specificity and very high selectivity of action are also due to its preferential accumulation in cells affected by the herpes virus.

It is highly active against Herpes simplex viruses of types 1 and 2; viruses causing chicken pox and shingles (Varicella zoster); Epstein-Barr virus (types of viruses are listed in ascending order of MAC value of acyclovir).

It is moderately active against CMV.

In case of herpes it prevents forming of new rash elements, reduces the possibility of cutaneous dissemination and visceral complications, accelerates crusts forming, reduces pain in the acute phase of herpes zoster. It has an immunostimulatory effect.

Indications

Treatment of primary and recurrent severe genital herpes (including in immune compromised patients) – oral and parenteral;

Prevention of frequently recurrent (6 or more cases per year) genital herpes (including in immune compromised patients) – oral.

Treatment of primary and recurrent herpes simplex with lesions of the skin and mucous membranes, caused by Herpes simplex virus type 1 and 2, in patients with immune impairment – orally, parenterally;

Prevention of herpes simplex in patients with immune impairment (including after transplantation and taking immunosuppressive drugs, HIV-infected patients, against a background of chemotherapy) – orally;

encephalitis caused by Herpes simplex virus types 1 and 2 – parenterally;

treatment of herpes zoster, caused by Varicella zoster virus in adults – orally; In immunocompromised patients and in generalized herpes zoster in immune-compromised patients, parenterally;

Prevention of Varicella zoster-induced herpes zoster shingles after the initial period of acyclovir parenteral use in all immunocompromised patients (includingч. After transplantation and while taking immunosuppressive drugs, HIV-infected patients, against the background of chemotherapy) – orally;

Herpes zoster with eye lesions – orally, parenterally;

Generalized infection in infants caused by Herpes simplex virus – parenterally;

pickpox in patients with unimpaired immunity within 24 hours after the appearance of the typical rash – orally, in patients with compromised immunity – parenterally.

Active ingredient

Composition

1 tablet contains:

the active ingredient:

acyclovir 200 mg.

How to take, the dosage

Interaction

Concomitant use with probenecid increases the average half-life and decreases the clearance of acyclovir.

Concomitant use with nephrotoxic drugs increases the risk of renal dysfunction.

Special Instructions

Caution should be exercised when prescribing Acyclovir to patients with impaired renal function and elderly patients due to the increased elimination half-life of acyclovir.

When using the drug, it is necessary to ensure adequate intake of fluids.

The efficacy of the treatment with the ointment is greater the earlier it is started.

In patients with immunodeficiency, repeated courses of treatment sometimes lead to viral resistance to acyclovir.

When taking the drug, renal function (blood urea and plasma creatinine levels) should be monitored.

Contraindications

Hypersensitivity (including to valacyclovir), children under 3 years of age (for solid LF).

With caution. Pregnancy, period of lactation.

Side effects

Overdose

Ingestion of 20 g of acyclovir has been reported. Symptoms: agitation, coma, convulsions, lethargy. Precipitation of acyclovir in the renal tubules is possible if its concentration exceeds renal tubule solubility (2.5 mg/ml).

Parenteral overdose (when given by bolus injection, or when used in high doses, or in patients whose water-electrolyte balance was not properly controlled): increased urea nitrogen, hypercreatininemia, renal dysfunction, lethargy, seizures, coma.

Treatment: maintenance of vital functions, hemodialysis.

Pregnancy use

Similarities